Jaye L. Viner

National Cancer Institute — United States

Medicine · Health Sciences

28h-index5.6kcitations104works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory mediators and NSAID effects(23), Cancer, Lipids, and Metabolism(18), Estrogen and related hormone effects(13), Histone Deacetylase Inhibitors Research(13), Computational Drug Discovery Methods(12)

Publications104 total

Perspective on This Article from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
2023Open Access
Supplementary Figures 1 - 8 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Perspective on this Article from A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer
2023Open Access
Data from A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer
2023Open Access
Supplementary Materials and Methods from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplemental Figure 1-8 from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Perspective on This Article from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
2023Open Access
Supplemental Figure 1-8 from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Data from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Data from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Data from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
2023Open Access
Supplementary Tables 1 - 2 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Data from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
2023Open Access
Data from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplement Figure Legends from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Supplementary Figures 1 - 8 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Materials and Methods from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Data from A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer
2023Open Access
Supplement Figure Legends from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Perspective on this Article from A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Ernest T. Hawk(28), Asad Umar(13), Ellen Richmond(6), Ronald A. Lubet(4), Caroline C. Sigman(4), William F. Anderson(3), Gary J. Kelloff(3), Vernon E. Steele(3), Levy Kopelovich(3), Julia Lawrence(3), Kenneth G. Linden(3), Ira Pastan(3), Paul J. Limburg(3), Lynn M. Matrisian(2), Monica M. Bertagnolli(2), Craig Eagle(2), Scott D. Solomon(2), Janet Wittes(2), Gary Gordon(2), James A. Crowell(2)